Sphere Fluidics appoints Edward Rayner as Non-Executive Director
Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth.
Sphere Fluidics appoints Dr. Graeme Daniels as Vice President of Sales and Marketing
Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions
Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows
Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions.
Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows
Latest software updates support FDA 21 CFR Part 11 compliance and a full IQ/OQ package for pharmaceutical quality assuranceSphere Fluidics’ Pico-Mine platform chosen by Biosyntia to accelerate synthetic biology and metabolic workflows
Cambridge, UK, and Copenhagen, Denmark - Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announces Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine® platform within its workflows.
Sphere Fluidics updates brand identity to align with ambitious, global commercial growth strategy
New branding reflects customer-centric approach and showcases pioneering, single cell analysis technologySphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.
Sphere Fluidics begins work with partners on 3DSecret program to investigate mechanisms of metastasis in cancer
3DSecret funded by European Innovation Council’s Pathfinder Open 2022, established under the EU Horizon Europe programSphere Fluidics appoints Richard Hammond as Chief Technical Officer
Key appointment forms part of ongoing plans to strengthen senior leadership team and support expansion of microfluidic product range for single cell analysis
Sphere Fluidics opens new laboratory facilities at Granta Park in Cambridgeshire, UK
Cambridge, UK - Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announces that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth. Doubling overall capacity, the laboratories enable the team’s accelerated expansion, and the development of new, innovative products.
Sphere Fluidics closes a $40 million funding round
Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.
Sphere Fluidics and ClexBio introduce CYTRIX Microfluidic Hydrogel Kit
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit.
Sphere Fluidics announces enhanced Cyto-Mine capability and performance
Simplified design reduces manufacturing time and offers improved functionality to help streamline antibody discovery, cell line development, cell therapy, and synthetic biology workflows.
Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.
Sphere Fluidics receives Queen’s Award for Enterprise
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, has be honored with a Queen’s Award for Enterprise for Innovation. The award recognises the Company’s excellence in patenting, developing and globally commercialising single cell analysis systems for biotherapeutic discovery.
Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and highly stable droplet generation and processing.
Sphere Fluidics and Peak Analysis and Automation introduce integrated micro-plate handling and single cell analysis capabilities
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leading supplier of intelligent laboratory automation solutions, today announced the optimization of the Cyto-Mine® Single Cell Analysis System through integration with PAA’s automated plate handler, S-LAB™. The addition of S-LAB to…
Sphere Fluidics introduces Cyto-Cellect Human IgGK Detection Kit
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to…
Sphere Fluidics expands into additional facility at Granta Park
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth.
CPI to showcase results from BioStreamline project developing novel biotherapeutics
CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project - featuring technology from Sphere Fluidics and Horizon Discovery Group - to optimise the development of novel therapeutics.
Sphere Fluidics closes a $4.8 million USD (£3.7 million) funding round
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment.
Fujifilm announces the introduction of a 10 week cell line development timeline
FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organisation (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
Sphere Fluidics hires 10 new UK and US staff in its plan to scale internationally
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites.
Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration for gene editing
Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.